Abstract: The present invention provides for numerous cell factors involved in a novel cellular pathway that is activated in response to ionizing radiation. Several cell factor activities are described which either complement the radioresistant DNA synthesis phenotype of Ataxia Telangiectasia cells, or inhibit DNA synthesis in the cell. Other cell factor activities are described which inhibit mitosis by arresting the cell cycle prior to cell division. It is contemplated that compositions comprising the subject factors will be useful as both research tools, and as therapeutic agents.

Abstract: Embodiments of the invention include formulations for the treatment of (AT) ataxia telangiectasia patient and asymptomatic AT heterozygous carriers. The subject formulations comprise one or more different prostaglandins and a pharmaceutically acceptable carrier. Preferably the prostaglandins are group E prostaglandins, prostaglandin E2 being particularly preferred. Other embodiments of the invention include methods of treating AT patients and AT carriers. These methods comprise the steps of administering an effective amount of a prostaglandin containing composition of the invention. Other embodiments of the invention include methods of treating AT patients and carriers with radiotherapy. The methods comprise the steps of administering and effective amount of a prostaglandin containing formulations of the invention and subsequently irradiating the subject with an amount of radiation sufficient to achieve the desired therapeutic effect.